to test methods and failure modes that can confound the aggregation ofresults. Of the 145 Traditional 510(k) submissions for cervical IBFDs initially screened,62 (42.8%) submissions were excluded leaving 83 submissions from 74 different manufacturers for analysis (Fig. 1)